PaLM Conf Minutes 2016-Mar-09

IHE PaLM call March 9

 

Attendees:

Alessandro Sulis,

Benoit Denisselle,

Carolyn Knapik,

Daniel Rutz,

Dmytro Rud,

Francesca Frexia,

Francois Macary,

Gunter Haroske,

James Wulkan,

James Harrison,

JD Nolen,

Laurent Lardin,

Mary Kennedy,

Megumi Kondo,

Naomi Ishii,

Raj Dash,

Riki Merrick,

Mark Law

• Housekeeping: Updates & checks on wiki, roster, milestones page – all
  • Roster should be available for next call. Could be a google spreadsheet, like IHE DCC does. More convenient for keeping it up to date.
  • Milestones page is now updated.
  • When there are no technical topics for agenda, call will be limited to first hour.
• Comment on XD-LAB made regulatory in France as of 2016 – François
  • The regulatory framework points the interoperability framework, and precisely, the specification which represents IHE XD-LAB in French. If the specification evolves, the regulatory framework is still valid: It points to the applicable version of the specification, hence the last one.
• Comment on LAW team contribution to IHE conformity assessment scheme
  • LAW almost ready for conformity assessment testing. The review of the CAS requested by Anne-Gaëlle, was performed by Riki, Ed and François.
• Discussion on SET detailed proposal (scope and specimen model …) – Alessandro
  • The proposal was shared incomplete so to have discussion
  • 1 single transaction and a pair of actors. Grouping of SET actors with actors of all profiles (LTW, LBL, LAW, ...)
  • Alessandro explains the major issues of discussion:
    • Issue 1: the scope of the profile: Which use cases?
      • Initial scope:
        • Workflow of specimen collection that are not completely covered in LBL profile, which is why we want to have SET
        • Exceptions to handling process when SOP was not followed, environmental conditions the specimen was exposed to (in biobanking, but not in clinical system) – example: androgen receptors on prostate samples – storage
        • Review ALL profiles in the PaLM domain to see, if any of these are already covered, or have other use cases related to specimen
        • LAW has some points of interest about specimen – specimen arrives at automation part
      • EPIC: Transitions of specimens across labs, across organizations
      • Raj: Workflows related to biobanking à needs additional data elements in the model. See the Specimen DAM project of HL7 and send feedback. Biobanking is not only for research. It’s used for all the genomics, in clinical labs.
        • Raj can share information with Alessandro – also involve Jim Harrison, since he is currently working in biobanking
        • DAM working on harmonizing with BRIDG model – calls are weekly on Fridays 12 – 1 PM ET (sign up for listserve at <a href="http://www.hl7.org/myhl7/managelistservs.cfm?ref=nav">http://www.hl7.org/myhl7/managelistservs.cfm?ref=nav</a>
      • JD: biobanking -> picking new identifiers
    • Issue 2: Which version of standard? V2? V3? FHIR?
      • To answer: check that SPM content from V2 is sufficient.
      • Check message type. Alternative could be SSUID?
    • Step 1: Consolidate the scope, use cases and related data analysis. Then, have a consensus on that.
    • Step 2: Select the most appropriate standard.
    • All sources of information to consolidate step 1 are welcome to be shared on the PaLM googleGroup.
  • April call will be one week earlier, because of the European connectathon.
  • Agenda items for April 6^th call:
    • SET (share materials a week prior to call)
    • White paper discussion (Raj)
    • F2F agenda May 23 – 25 Berlin, Germany
    • LSH Deep Dive (John Hopson)